| Literature DB >> 30466721 |
Adrian D K Le1, Lawrence Enweze1, Malcolm R DeBaun1, Jason L Dragoo2.
Abstract
Platelet-rich plasma (PRP) is a promising treatment for musculoskeletal maladies and clinical data to date have shown that PRP is safe. However, evidence of its efficacy has been mixed and highly variable depending on the specific indication. Additional future high-quality large clinical trials will be critical in shaping our perspective of this treatment option. The heterogeneity of PRP preparations, both presently and historically, leads sweeping recommendations about its utility impossible to make. This heterogeneity has also made interpreting existing literature more complicated.Entities:
Keywords: Augmentation; Orthobiologics; Osteoarthritis; PRP; Platelet-rich plasma; Regenerative medicine; Tendinopathy
Mesh:
Year: 2019 PMID: 30466721 DOI: 10.1016/j.csm.2018.08.001
Source DB: PubMed Journal: Clin Sports Med ISSN: 0278-5919 Impact factor: 2.182